Associate Professor, Urology, University of Pittsburgh School of Medicine
Urology
Dr. Jeffrey R. Gingrich, MD
|
|
Give Review
Jeffrey Gingrich works in the field of Urology. He went to University of Michigan Medical School. He received awards:"Fellow (FACS)". Jeffrey Gingrich is also a published MD. He has 51 paper published. The most recent paper is: A gene hunting we will go! Doctor Jeffrey R. Gingrich, MD accepts Medicare payments and is listed with Medicare.gov.
Publications
- Toward improved effectiveness of Bladder cancer immunotherapy.
- Influence of E. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats.
- 5α-Reductase Inhibition Coupled with Short Off Cycles Increases Survival in the LNCaP Xenograft Prostate Tumor Model on Intermittent Androgen Deprivation Therapy.
- CLT1 Targets Bladder Cancer through Integrin ?5?1 and CLIC3.
- Epidermal inclusion cyst presenting as a palpable scrotal mass.
- Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer.
- Investigation of phosphoprotein signatures of archived prostate Cancer tissue specimens via proteomic analysis.
- Hyperthermia and intravesical therapy: emerging one-two punch for Bladder cancer?
- Hypoexpression and epigenetic regulation of candidate tumor suppressor gene CADM-2 in human prostate Cancer.
- Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate Cancer.
- The Prostate Cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled ...
- Treatment of inflammatory and neuropathic pain by uncoupling Src from the NMDA receptor complex.
- Unique domain anchoring of Src to synaptic NMDA receptors via the mitochondrial protein NADH dehydrogenase subunit 2.
- Prostate-specific expression of p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate Cancer progression and prolong survival.
- Effect of flaxseed supplementation on prostatic carcinoma in transgenic mice.
- Prostate Cancer gene therapy.
- Surgical approaches to local failure after definitive therapy.
- Investigational therapies for non-muscle invasive Bladder cancer.
- Bladder cancer: chemohyperthermia for Bladder cancer-clinically effective?
- Lymphoepithelioma-like carcinoma of the urinary Bladder.
- Src in synaptic transmission and plasticity.
- Transrectal gene therapy of the Prostate in the canine model.
- The impact of bcl-2 expression and bax deficiency on Prostate homeostasis in vivo.
- Gene therapy for prostate Cancer: where are we now?
- Combination of IFNα and poly-I:C reprograms Bladder cancer microenvironment for enhanced CTL attraction.
- Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive Bladder cancer.
- Bcl-2 accelerates multistep Prostate carcinogenesis in vivo.
- Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse Prostate (TRAMP) model.
- Metastatic prostate Cancer in a transgenic mouse.
- Differential expression of C-CAM cell adhesion molecule in Prostate carcinogenesis in a transgenic mouse model.
- Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in Prostate gland...
- Impact of Urethral injury management on the treatment and outcome of concurrent pelvic fractures.
- Establishment and characterization of a new human prostatic carcinoma cell line (DuPro-1).
- The impact of PSA on prostate Cancer management. Can we abandon routine staging pelvic lymphadenectomy?
- The natural progression of adenocarcinoma of the epididymis.
- Immunotherapeutic agents for the management of BCG refractory non-muscle invasive Bladder cancer.
- A transgenic mouse prostate Cancer model.
- U19/Eaf2 knockout causes lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma and prostatic intraepithelial neoplasia.
- Androgen-independent prostate Cancer progression in the TRAMP model.
- Combination versus single agent therapy in effecting complete therapeutic response in human Bladder cancer: analysis of cisplatin and/or 5-fluorouracil in an in vivo s...
- Importance of delayed imaging for blunt Renal trauma.
- The therapeutic impact of dipyridamole: chemopotentiation of the cytotoxic combination 5-fluorouracil/cisplatin in an animal model of human Bladder cancer.
- A gene hunting we will go!
- Gene therapy in urologic oncology.
- Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: clinical characteristics and outcome.
- Imaging findings of hemorrhagic cystitis in pediatric oncology patients.
- Ethics of postmortem sperm retrieval: ethics of sperm retrieval after death or persistent vegetative state.
- Inducible gene expression in the nervous system of transgenic mice.
- Production and characterization of polyclonal antibodies recognizing the intracytoplasmic third loop of the 5-hydroxytryptamine1A receptor.
- The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer.
Schools
University Of Michigan Medical School
University Mich Med School
Duke University Med Center
Baylor College Med
Procedures Preformed
- Cystectomy
- Cystourethroscopy and TransUrethral Resection of Bladder Neck
- Kidney and Ureter Removal
- Kidney Stone Removal
- View All
Conditions Treated
- Bladder Cancer
- Bladder Infection
- Bladder Stones
- Blood in Urine (Hematuria)
- View All
Doctors Specialties
- Urology
Accepted Insurances
Awards
- Fellow (FACS)
Education
-
Duke University Hospital -
University of Michigan Hospitals and Health Centers -
University of Michigan Medical School
Hospital
-
UPMC Presbyterian Shadyside
Drug Facts
| NPI NUMBER | 1518930528 | |
| NPPES Provider LastName | GINGRICH | |
| NPPES Provider FirstName | JEFFREY | |
| NPPES Provider ZIPCode | 152321300 | |
| NPPES Provider State | PA | |
| Specialty Description | Urology | |
| Total Claim Count | 506.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1518930528 |
| Last Name Of The Provider | GINGRICH |
| First Name Of The Provider | JEFFREY |
| View All |
Similar Doctors
|
|
Dr. Kevin P. Bordeau, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Walter F. Odonnell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Falk K. Arnheim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas R. Hakala, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kevin B. Traub, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel I. Gup, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arnold J. Sholder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joel B. Nelson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Louis A. D'Agostino, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andres F. Correa, MD |
|
|
Dr. Thomas W. Fuller, MD |
|
|
Dr. Anne G. Dudley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Benjamin T. Ristau, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Rebecca A. Renze, PA-C
This Doctor is OpenDoctor Recommended.
|
|
|
Kristen L. Yerman, PA-C |